Kintor Pharmaceutical (HKSE:09939) Institutional Ownership : 2.94% (As of Jun. 15, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Kintor Pharmaceutical's institutional ownership is 2.94%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Kintor Pharmaceutical's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Kintor Pharmaceutical's Float Percentage Of Total Shares Outstanding is 0.00%.

Kintor Pharmaceutical Institutional Ownership Historical Data

The historical data trend for Kintor Pharmaceutical's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical Institutional Ownership Chart

Kintor Pharmaceutical Historical Data

The historical data trend for Kintor Pharmaceutical can be seen below:

	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Institutional Ownership	7.72	4.99	4.98	4.98	3.12	2.99	2.99	2.99	2.98	2.94

Kintor Pharmaceutical Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Kintor Pharmaceutical (HKSE:09939) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (HKSE:09939) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

KNTPF:USA

Address

No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.kintor.com.cn

Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on the research and development of medical products.

Executives

Tong Youzhi	2101 Beneficial owner
Kt International Investment Limited	2101 Beneficial owner
Guo Chuangxing	2201 Interest of corporation controlled by you
Kg Development Limited	2101 Beneficial owner
Nomura Holdings, Inc.	2201 Interest of corporation controlled by you
Tong Youzhi	2201 Interest of corporation controlled by you
Zhu Hai Ge Li Jin Rong Tou Zi Guan Li You Xian Gong Si	2101 Beneficial owner
Zhu Hai Ge Li Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Sovereign Fiduciaries (hong Kong) Limited
Kiya Company Limited
Lian Xiang Kong Gu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Nan Ming You Xian Gong Si	2201 Interest of corporation controlled by you
Shi Xian You Xian Gong Si	2101 Beneficial owner

Kintor Pharmaceutical (HKSE:09939) Headlines

No Headlines